Good or Poor Responses of Hemostatic Molecular Markers in Patients with Hematopoietic Disorders After Treatment of Disseminated Intravascular Coagulation

Changes of hemostatic markers in 226 patients with disseminated intravascular coagulation (DIC) and hematopoietic disorders were examined after treatment of DIC. The changes in prothrombin time (PT) ratio, fibrinogen, fibrin and fibrinogen degradation products (FDP), antithrombin, and protein C, thrombin-antithrombin complex (TAT), plasmin-plasmin inhibitor complex (PPIC), and soluble fibrin monomer complex (SFMC) in all patients with DIC were significant during the clinical course of DIC, but those of D-dimer, thrombomodulin (TM), tissue factor (TF), and tissue factor pathway inhibitor (TFPI) were not. Activated partial thromboplastin time (aPTT) and PT were significantly longer in the poor response group than in good response group. Plasma levels of FDP, TAT, PPIC, SFMC, TM, and DIC score were significantly higher in poor response group than in good response. Protein C and antithrombin levels were significantly lower in poor response group than in good response group. The changes of PT ratio, fibrinogen, FDP, DIC score, antithrombin, plasmin inhibitor, and protein C were significant in the good response group, but these levels were not significant in the poor response group. The changes in plasma TAT and SFMC levels were significant in the good response group but were not in poor response group. The changes in D-dimer, TM, TF, or TFPI were not significant in both groups. These findings suggest that anticoagulant agents should be administered at levels below TAT 40 ng/mL or SFMC 300 μg/mL in patients with DIC and hematopoietic disorders.

[1]  E. Gabazza,et al.  Hemostatic molecular markers before the onset of disseminated intravascular coagulation , 1999, American journal of hematology.

[2]  E. Gabazza,et al.  Increased truncated form of plasma tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation , 1999, American journal of hematology.

[3]  E. Gabazza,et al.  Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[4]  H. Shiku,et al.  Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries , 1998, American journal of hematology.

[5]  H. Shiku,et al.  Increased plasma‐soluble fibrin monomer levels in patients with disseminated intravascular coagulation , 1996, American journal of hematology.

[6]  H. Shiku,et al.  Outcome of Disseminated Intravascular Coagulation in Relation to the Score when Treatment was Begun , 1995, Thrombosis and Haemostasis.

[7]  H. Shiku,et al.  Tissue factor expression in endothelial cells in health and disease , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[8]  D. Hoppensteadt,et al.  TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. , 1995, Thrombosis research.

[9]  M. Blombäck,et al.  Soluble fibrin: A predictor for the development and outcome of multiple organ failure , 1994, American journal of hematology.

[10]  M. Nakagawa,et al.  Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC)--a multicenter co-operative double-blind trial in comparison with heparin. , 1993, Thrombosis research.

[11]  S. Thompson,et al.  Prothrombin Activation Fragment 1 + 2 and Thrombin Antithrombin III Complexes in Patients with Angina Pectoris: Relation to the Presence and Severity of Coronary Atherosclerosis , 1993, Thrombosis and Haemostasis.

[12]  B. Shen,et al.  Diagnostic value of clonality of surface immunoglobulin light and heavy chains in malignant lymphoproliferative disorders , 1993, American journal of hematology.

[13]  Koji Suzuki,et al.  Hemostatic study before onset of disseminated intravascular coagulation , 1993, American journal of hematology.

[14]  G. Müller‐Berghaus.  Pathophysiologic and Biochemical Events in Disseminated Intravascular Coagulation: Dysregulation of Procoagulant and Anticoagulant Pathways , 1989, Seminars in thrombosis and hemostasis.

[15]  R. Bick.  Disseminated Intravascular Coagulation and Related Syndromes: A Clinical Review , 1988, Seminars in thrombosis and hemostasis.

[16]  L. Poller.  A Simple Nomogram for the Derivation of International Normalised Ratios for the Standardisation of Prothrombin Times , 1988, Thrombosis and Haemostasis.

[17]  H. Wada,et al.  Anticoagulant Activity in Cell Homogenate of Adult T Cell Leukemia , 1988, Thrombosis and Haemostasis.

[18]  H. Pelzer,et al.  Determination of Human Thrombin-Antithrombin III Complex in Plasma with an Enzyme-Linked Immunosorbent Assay , 1988, Thrombosis and Haemostasis.

[19]  J. Mimuro,et al.  Monoclonal antibodies to discrete regions in alpha 2-plasmin inhibitor. , 1987, Blood.

[20]  Vogel Ge.  The treatment of consumption coagulopathy. , 1986 .

[21]  S. Lewis,et al.  Reliability and Clinical Impact of the Normalization of the Prothrombin Times in Oral Anticoagulant Control , 1985, Thrombosis and Haemostasis.

[22]  D. Rylatt,et al.  An immunoassay for human D dimer using monoclonal antibodies. , 1983, Thrombosis research.

[23]  T Maekawa,et al.  Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. , 1983, Bibliotheca haematologica.

[24]  G. Kōsaki,et al.  FOY: [ethyl p-(6-guanidinohexanoyloxy) benzoate] methanesulfonate as a serine proteinase inhibitor. II. In vivo effect on coagulofibrinolytic system in comparison with heparin or aprotinin. , 1981, Thrombosis research.

[25]  S. Imaoka,et al.  FOY: [ethyl P-(6-guanidinohexanoyloxy) benzoate] methanesulfonate as a serine proteinase inhibitor. I. Inhibition of thrombin and factor Xa in vitro. , 1980, Thrombosis research.